SOURCE: SNN Incorporated

SNN Incorporated

October 27, 2015 08:43 ET

StockNewsNow.com Publishes New SNNLive Video Interview With CEL-SCI Corporation

LOS ANGELES, CA--(Marketwired - October 27, 2015) - StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Video Interview with Geert Kersten, CEO of CEL-SCI Corporation (NYSE MKT: CVM), is involved in the research and development of investigational immunotherapy products for the treatment of cancer and infectious diseases, according to the Company's website (see here: www.CEL-SCI.com). The video interview was recorded on Thursday, October 15th, 2015 at the Dawson James Small Cap Growth Conference 2015 in Jupiter, FL.

Click the following link to watch the SNNLive Video Interview on StockNewsNow.com:

CEL-SCI Corporation -- Research and Development of Immunotherapy Products for Treatment of Cancer and Infectious Diseases

You can follow Stock News Now on FACEBOOK, TWITTER, LINKEDIN, YOUTUBE, and STOCKTWITS

Please review important disclosures on our website at: http://stocknewsnow.com/legal.php#disclaimer

About CEL-SCI Corporation

CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. Its lead investigational therapy, Multikine (Leukocyte Interleukin, Injection), is currently being studied in a pivotal Phase 3 clinical trial as a potential neoadjuvant treatment for patients with squamous cell carcinoma of the head and neck. If the study endpoint, which is a 10% improvement in overall survival of the subjects treated with the Multikine treatment regimen plus the current SOC as compared to subjects treated with the current SOC only, is satisfied, the study results will be used to support applications that the Company plans to submit to regulatory agencies in order to seek commercial marketing approvals for Multikine in major markets around the world. Additional clinical indications for Multikine that are being investigated include the treatment of cervical dysplasia in HIV/HPV co-infected women, and the treatment of peri-anal warts in HIV/HPV co-infected men and women. A Phase 1 trial of the former indication has been completed at the University of Maryland. The latter indication is now in a Phase 1 trial in conjunction with the U.S. Naval Medical Center, San Diego, under a CRADA, and at UCSF.

CEL-SCI is also developing its pre-clinical L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology for the potential treatment of pandemic influenza in hospitalized patients and as a potential vaccine for the treatment of rheumatoid arthritis.

The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

Company description and for more information: www.CEL-SCI.com

About StockNewsNow.com

StockNewsNow.com is a microcap financial news portal that features news and insights from the microcap and emerging growth financial community. StockNewsNow.com is a multimedia destination hub for information about microcap and emerging growth public and private companies, market events, news, bulletins, stock quotes, expert commentary and company profiles that feature user-generated video, SNN-produced video like SNNLive CEO video interviews, as well as research reports, radio interviews, PowerPoint presentations, articles, and their latest news and headlines. Users can engage directly and share the information provided through social media.

Follow the companies YOU want to know more about; read and watch content from YOUR favorite microcap, emerging growth financial experts; register to attend financial conferences of YOUR choosing; find microcap and emerging growth financial professionals that YOU may be looking for -- all here on StockNewsNow.com.

Embedded Video Available: https://www.youtube.com/watch?v=hXbo8gUh1pk

Contact Information